# US 2026/0216373 A1 · Gene Therapy Constructs for the Treatment of Pompe Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216373 A1
- Document ID: US20260216373A1
- Status: Published application
- Kind: A1
- Application number: 19/147,498
- Filed: 2024-01-12
- Published: 2026-07-30
- Earliest claimed: 2023-01-13
- Assignees: Amicus Therapeutics, Inc.
- Applicants: Amicus Therapeutics, Inc.
- Inventors: Hung V. Do
- Web page: https://patentgrep.com/patent/US20260216373A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 48/0083: {characterised by an aspect of the administration regime}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C07K 14/65: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 9/2408: {acting on alpha -1,4-glucosidic bonds}
- C12N 15/86: Viral vectors
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0306: Animal model for genetic diseases
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12Y 302/0102: Alpha-glucosidase (3.2.1.20)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12Y: ENZYMES

## Abstract

The present disclosure relates to recombinant adeno-associated virus (rAAV) delivery of an acid alpha-glucosidase (GAA) polynucleotide. The disclosure provides rAAV vectors and methods of using the rAAV vectors for GAA gene therapy for Pompe disease.

## Claims

### Claim 1

A gene therapy vector comprising a nucleic acid construct encoding a polypeptide comprising:
a therapeutic protein comprising acid alpha-glucosidase (GAA);
a CIMPR-binding peptide comprising a variant IGF2 (vIGF2) peptide; and
a signal peptide comprising a binding immunoglobulin protein (BiP) signal peptide.

### Claim 2 (depends on 1)

The gene therapy vector of claim 1, further comprising an adeno-associated viral (AAV) vector.

### Claim 3 (depends on 2)

The gene therapy vector of claim 2, wherein the AAV vector is an AAV9 vector.

### Claim 4 (depends on 1, 2, 3)

The gene therapy vector of any one of claims 1-3, further comprising a promoter.

### Claim 5 (depends on 4)

The gene therapy vector of claim 4, wherein the promoter comprises a cytomegalovirus (CMV) early enhancer/chicken R actin (CAG) promoter.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The gene therapy vector of any one of claims 1-5, wherein the GAA has an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 1-4.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The gene therapy vector of any one of claims 1-6, wherein the GAA has an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOS: 1-4.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The gene therapy vector of any one of claims 1-7, wherein the GAA has an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-4.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The gene therapy vector of any one of claims 1-8, wherein the vIGF2 peptide has an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 5-19.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The gene therapy vector of any one of claims 1-9, wherein the vIGF2 peptide has an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOS: 5-19.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The gene therapy vector of any one of claims 1-10, wherein the vIGF2 peptide has an amino acid sequence selected from the group consisting of SEQ ID NOS: 5-19.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The gene therapy vector of any one of claims 1-11, wherein the nucleic acid encoding the vIGF2 peptide has a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS 25 or 26.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The gene therapy vector of any one of claims 1-8, wherein the BiP signal peptide has an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 20-24.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The gene therapy vector of any one of claims 1-9, wherein the BiP signal peptide has an amino acid sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOS: 20-24.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The gene therapy vector of any one of claims 1-10, wherein the BiP signal peptide has an amino acid sequence selected from the group consisting of SEQ ID NOS: 20-24.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method of treating Pompe disease in a subject, the method comprising administering a therapeutically effective amount of the gene therapy vector of any one of claims 1-15.

### Claim 17 (depends on 16)

The method of claim 16, wherein the gene therapy vector is administered systemically.

### Claim 18 (depends on 16, 17)

The method of claim 16 or 17, wherein the therapeutically effective amount of the gene therapy vector is in a range of from about 1×1012 to about 1×1015 vg.

### Claim 19 (depends on 6, 7, 8)

The method of any one of claims 6-8, wherein the therapeutically effective amount of the gene therapy vector is in a range of from about 5×1012 to about 1×1014 vg.

### Claim 20 (depends on 16, 17, 18, 19)

The method of any one of claims 16-19, wherein the therapeutically effective amount of the composition is about 2.5×1013 vg or about 5×1013 vg.

### Claim 21 (depends on 16, 17, 18, 19, 20)

The method of any one of claims 16-20, wherein the gene therapy vector is administered via a route selected from the group consisting of intrathecal, intracisternal, lumbar puncture, intracranial, intracerebroventricular, intraparenchymal, intravenous and combinations thereof.

### Claim 22 (depends on 16, 17, 18, 19, 20, 21)

The method of any one of claims 16-21, wherein gene therapy vector is not administered in combination with a non-ionic, low-osmolar contrast agent.

### Claim 23 (depends on 16, 17, 18, 19, 20, 21)

The method of any one of claims 16-21, wherein gene therapy vector is administered in combination with a non-ionic, low-osmolar contrast agent.

### Claim 24 (depends on 23)

The method of claim 23, wherein the non-ionic, low-osmolar contrast agent is selected from the group consisting of iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol, ioxilan, and combinations thereof.

### Claim 25 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 16-24, wherein the method reduces glycogen storage in patient cells.

### Claim 26 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 16-25, wherein the method reduces glycogen storage in one or more of skeletal and cardiac muscles, the diaphragm, and the central nervous system (CNS).
